Effects of exenatide and open-label SGLT2 inhibitor treatment, given in parallel or sequentially, on mortality and cardiovascular and renal outcomes in type 2 diabetes: insights from the EXSCEL trial

Abstract Background Sodium-glucose cotransporter-2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1 RA) improve cardiovascular and renal outcomes in patients with type 2 diabetes through distinct mechanisms. However, evidence on clinical outcomes in patients treated with both...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Lindsay E. Clegg, Robert C. Penland, Srinivas Bachina, David W. Boulton, Marcus Thuresson, Hiddo J. L. Heerspink, Stephanie Gustavson, C. David Sjöström, James A. Ruggles, Adrian F. Hernandez, John B. Buse, Robert J. Mentz, Rury R. Holman
Formato:	Artigo
Idioma:	Inglês
Publicado em:	BMC 2019-10-01
coleção:	Cardiovascular Diabetology
Assuntos:	SGLT2 inhibitor GLP-1 receptor agonist Exenatide Cardiovascular outcomes eGFR slope Type 2 diabetes mellitus
Acesso em linha:	http://link.springer.com/article/10.1186/s12933-019-0942-x
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!